PROTECT

Gastrointestinal tumors
Esophageal and Gastric Cancer
Neoadjuvant Therapy
The PROTECT trial will test the hypothesis that proton (PT) -enabled radiation dose reductions to sensitive, normal tissues will result in lower rates of treatment-related pulmonary complications in esophageal cancer compared to standard photon therapy (XT).